Table 2.
Baseline clinicopathological characteristics in the current study cohort.
| GPS | Overall Study Group (n = 102) |
Group I GPS 0 (n = 59) |
Group II GPS 1 (n = 26) |
Group III GPS 2 (n = 17) |
|---|---|---|---|---|
| Male/female | 56/46 | 34/25 | 14/12 | 8/9 |
| Median age (range), years | 62 (18–95) | 59 (18–85) | 65 (36–95) | 60 (23–81) |
| BMI (median, range) | 26.9 (16.9–40.8) | 28.0 (16.9–38.0) | 26.0 (18.0–40.8) | 26.0 (18.0–37.1) |
| Weight disorder | ||||
| Cachexia (BMI < 20 kg/m2) | 9/71 (12.7%) | 4/39 (10.3%) | 4/19 (21.1%) | 1/10 (10.0%) |
| Obesity (BMI > 30 kg/m2) | 20/71 (28.2%) | 14/39 (35.9%) | 3/19 (15.8%) | 3/10 (30.0%) |
| ECOG PS | ||||
| 0–1 | 82 (80.4%) | 52 (88.1%) | 19 (73.1%) | 11 (64.7%) |
| 2–4 | 20 (19.6%) | 7 (11.9%) | 7 (26.9%) | 6 (35.3%) |
| CCI (Median, range) | 6 (0–13) | 5 (0–12) | 7.5 (2–11) | 7 (4–13) |
| B-symptoms | ||||
| No | 77 (75.5%) | 49 (83.1%) | 17 (65.4%) | 11 (64.7%) |
| Yes | 25 (24.5%) | 10 (16.9%) | 9 (34.6%) | 6 (35.3%) |
| Primary sites | ||||
| Pancreatic | 41 (40.2%) | 27 (45.8%) | 9 (34.6%) | 5 (29.4%) |
| Intestine | 44 (43.1%) | 24 (40.7%) | 13 (50.0%) | 7 (41.2%) |
| - Gastric | 7 (6.9%) | 4 (6.8%) | 1 (3.8%) | 2 (11.8%) |
| - Jejunoileal | 25 (24.5%) | 15 (25.4%) | 7 (26.9%) | 3 (17.6%) |
| - Appendix | 5 (4.9%) | 4 (6.8%) | 1 (3.8%) | - |
| - Colon | 3 (2.9%) | 1 (1.7%) | 1 (3.8%) | 1 (5.9%) |
| - Rectum | 4 (3.9%) | - | 3 (11.5%) | 1 (5.9%) |
| Unknown Primary | 17 (16.7%) | 8 (13.5%) | 4 (15.4%) | 5 (29.4%) |
| Multifocal | 11 (10.8%) | 6 (10.1%) | 3 (11.5%) | 2 (11.7%) |
| Metastasis | ||||
| Yes | 53 (51.9%) | 23 (39.0%) | 17 (65.4%) | 13 (76.5%) |
| Carcinoid Syndrome | ||||
| No | 83 (81.4%) | 47 (79.7%) | 20 (76.9%) | 16 (94.1%) |
| Yes | 19 (18.6%) | 12 (20.3%) | 6 (23.1%) | 1 (5.9%) |
| Albumin (g/L) (median, range) | ||||
| ≥35 g/L | 71 (69.6%) | 55 (93.2%) | 15 (57.7%) | 1 (5.9%) |
| <35 g/L | 31 (30.4%) | 4 (6.8%) | 11 (42.3%) | 16 (94.1%) |
| CRP (mg/dL) (median, range) | ||||
| ≤10 mg/dL | 72 (70.6%) | 58 (98.3%) | 13 (50.0%) | 1 (5.9%) |
| >10 mg/dL | 30 (29.4%) | 1 (1.7%) | 13 (50.0%) | 16 (94.1%) |
| Chromogranin A median (range) | 179 (29–56,200) | 155 (29–13,600) | 209 (41.2–8856) | 196 (45–56,200) |
| Histological Grading | ||||
| NET (G1) | 24 (24.7%) | 18 (32.7%) | 4 (16.0%) | 2 (11.8%) |
| NET (G2) | 49 (50.5%) | 30 (54.5%) | 14 (56.0%) | 5 (29.4%) |
| NET(G3) | 6 (5.9%) | 3 (5.1%) | 1 (3.8) | 2 (11.8%) |
| Ki-67 (median, range) | 5% (1–40%) | 4% (1–30%) | 5% (1–20%) | 5% (1–40%) |
| NEC | 20 (19.6%) | 5 (8.5%) | 7 (26.9%) | 8 (47.1%) |
| - Small cell type | 17 (16.7%) | 5 (8.5%) | 5 (19.2%) | 7 (41.2%) |
| - Large cell type | 3 (2.9%) | - | 2 (7.7%) | 1 (5.9%) |
| Ki-67 (median, range) | 80% (40–90%) | 80% (60–80%) | 80% (40–80%) | 75% (40–90%) |
| SSTR2 | ||||
| Negative | 30 (41.1%) | 15 (34.9%) | 8 (40.0%) | 7 (70.0%) |
| Positive | 43 (58.9%) | 28 (65.1%) | 12 (60.0%) | 3 (30.0%) |
| UICC | ||||
| I | 14 (13.7%) | 11 (18.6%) | 3 (11.5%) | - |
| II | 11 (10.8%) | 9 (15.3%) | 2 (7.7%) | - |
| III | 24 (23.5%) | 16 (27.1%) | 5 (19.2%) | 3 (17.6%) |
| IV | 53 (51.9%) | 23 (39.0%) | 16 (61.5%) | 14 (82.4%) |
BMI, body mass index; CCI, Charlson Comorbidity Index; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; GPS, Glasgow Prognostic Score; MEN, multiple endocrine neoplasia; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; NSE; neuronspecific enolase; SSTR2, somatostatin-receptor-subtype 2; UICC, Union internationale contre le cancer.